RxDoctor Payments DataLook up a doctor →

Rikesh Desai, MD

Geriatric Medicine · Surprise, AZNPI 1396966743

Payments from drug & device makers

$8,460in general payments, 2019–2025

Across 368 payments — averaging $22.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$683
  • Bayer$430
  • GSK$419
  • Novo Nordisk$402
  • Amgen$360
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$8,460100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,460 in reported general payments places this provider in the 90th percentile of 75 geriatric medicine providers in Arizona.

See all geriatric medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$291,627
Medicare patients
537
Services billed
3,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin101$147,756
EliquisApixaban102$139,073
RybelsusSemaglutide63$122,750
FarxigaDapagliflozin Propanediol77$108,329
JanuviaSitagliptin Phosphate72$96,809
MounjaroTirzepatide60$68,382
OzempicSemaglutide33$57,417
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$44,979
XareltoRivaroxaban30$35,431
Tresiba Flextouch U-200Insulin Degludec39$32,043
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$25,754
Rosuvastatin Calcium537$11,220
Fiasp FlextouchInsulin Aspart (Niacinamide)12$7,505
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$7,345
Atorvastatin Calcium689$7,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$402$180,16796 claims
Boehringer IngelheimJardiance$313$147,756101 claims
PfizerEliquis, Premarin$165$141,490114 claims
AstraZenecaFarxiga$2,069$108,32977 claims
MerckJanuvia$105$96,80972 claims
Lilly USA, LLCMounjaro$142$68,38260 claims
GSKTrelegy Ellipta$419$44,97933 claims
Johnson & JohnsonXarelto$192$35,43130 claims
AbbVieSynthroid$683$2,82961 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 75 geriatric medicine providers in Arizona.

Other geriatric medicine in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →